[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mohammed V University in Rabat\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":75},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100629885","pharmacogenetic-guided-antidepressant-treatment-in-depression-100629885",false,"NCT07480486","Pharmacogenetic-Guided Antidepressant Treatment in Depression","Pharmacogenetic-Guided Antidepressant Treatment for Major Depressive Disorder: A Randomized Controlled Trial in Morocco","PGX-MDD","Inclusion Criteria:\n\n* Diagnosis of a depressive disorder (major depressive disorder, depressive episode, or persistent depressive disorder) confirmed by a healthcare professional according to DSM-5 or ICD-10 criteria.\n* Aged 18 years or older at the time of enrollment.\n* Clinical indication for initiation or modification of antidepressant pharmacotherapy.\n* Ability to understand study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Current acute psychotic disorder, manic episode, or uncontrolled bipolar disorder.\n* Current pregnancy or breastfeeding.\n* Use of medications with clinically significant interactions with antidepressants.\n* Any severe medical condition that, in the opinion of the investigator, would compromise participant safety or study integrity.","ALL","18 Years",{"count":20,"type":21},570,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this clinical trial is to evaluate whether using pharmacogenetic testing to guide antidepressant treatment can improve outcomes in adults with major depressive disorder in Morocco. Depression is a common mental health condition, and finding the most effective antidepressant for a patient can take time. Some individuals do not respond well to the first medication prescribed or may experience side effects.\n\nPharmacogenetic testing examines genetic variations that can influence how a person processes certain medications. Information about genes involved in drug metabolism, such as CYP2D6 and CYP2C19, may help clinicians choose antidepressants and adjust doses more appropriately for each patient.\n\nThe main question this study aims to answer is whether treatment guided by pharmacogenetic test results leads to higher remission rates of depressive symptoms compared with usual clinical care.\n\nIn this study, participants diagnosed with major depressive disorder will be randomly assigned to one of two groups. In the pharmacogenetic-guided group, clinicians will receive the patient's genetic test results and may use this information to guide antidepressant selection and dosing. In the usual care group, antidepressant treatment will be prescribed according to standard clinical practice without access to pharmacogenetic information.\n\nParticipants will receive antidepressant treatment and will be followed for 12 weeks. During this period, depressive symptoms will be evaluated using standardized clinical questionnaires, including the Patient Health Questionnaire (PHQ-9). Information on treatment response, medication tolerance, and adverse effects will also be collected.\n\nThis study aims to provide evidence on the potential role of pharmacogenetic-guided treatment in improving depression management and to support the development of personalized medicine approaches in psychiatric care in Morocco.",[27],"Depression - Major Depressive Disorder",[29,30,31,32,33,34,35],"Pharmacogenetics","Pharmacogenomics","Antidepressant Treatment","Precision Medicine","Major Depressive Disorder","Depression","Personalized Medicine","NOT_YET_RECRUITING","2026-04-04",{"date":39,"type":40},"2026-04-09","ACTUAL",{"date":42,"type":21},"2026-04-01",{"date":44,"type":21},"2027-05-01",{"name":46,"class":47},"Mohammed V University in Rabat","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100618873","posturography-rehabilitation-and-pelvic-floor-training-on-urinary-incontinence-in-women-100618873","NCT07337278","Posturography Rehabilitation and Pelvic Floor Training on Urinary Incontinence in Women","Effect of Lumbopelvic Rehabilitation Using Posturography Combined With Pelvic Floor Training on Urinary Incontinence in Women","Inclusion Criteria:\n\n* Female participants aged between 18 and 65 years\n* Presence of clinical signs of urinary incontinence (stress urinary incontinence and\u002For urge urinary incontinence and\u002For mixed urinary incontinence) diagnosed according to the International Continence Society (ICS) terminology\n* USP (urinary symptom profile) scores for stress urinary incontinence and\u002For overactive bladder ≥ 1\n* Normal neuro-perineal examination\n* Written informed consent provided prior to participation in the study\n\nExclusion Criteria:\n\n* Known detrusor overactivity or reduced bladder compliance of neurological origin\n* Associated voiding dysfunction, defined as a Urinary Symptom Profile (USP) dysuria subscale score ≥ 1\n* Known organic or morphological pathology of the lower urinary tract\n* Pelvic organ prolapse grade II or higher according to the Pelvic Organ Prolapse Quantification system (POP-Q)\n* Current urinary tract infection or vaginal infection\n* Cognitive or visual impairments that may interfere with understanding or performing the exercise program\n* Pregnant women or women within 10 months postpartum\n* Anticholinergic medication use or hormone replacement therapy within the last 6 months\n* Recent pelvic or abdominal surgery within the last 6 months","FEMALE","65 Years",{"count":59,"type":21},78,[24],"The goal of this clinical trial is to evaluate whether lumbopelvic postural rehabilitation combined with pelvic floor muscle training (PFMT) is more effective than PFMT alone in women with urinary incontinence. The main questions it aims to answer are:\n\n* Does the addition of lumbopelvic postural rehabilitation improve the severity of urinary incontinence as measured by the ICIQ-UI-SF questionnaire?\n* Does it improve urinary symptom profile, pelvic floor muscle strength, patient-reported overall improvement, and quality of life compared to PFMT alone?\n\nParticipants will be randomly assigned to one of two groups:\n\n* Experimental group (Group A): PFMT (3 sessions\u002Fweek) plus lumbopelvic postural rehabilitation (2 sessions\u002Fweek) for 12 weeks.\n* Control group (Group B): PFMT alone (3 sessions\u002Fweek) for 12 weeks. Participants will perform pelvic floor exercises in supine and seated positions, with supervised sessions at the hospital and home exercises. Postural rehabilitation includes stability and mobility exercises for the lumbopelvic region using Posturography. Outcomes will be assessed at baseline, at 6 weeks, and at 12 weeks.",[63],"Urinary Incontinence",[65],"Urinary incontinence, Pelvic floor, Lumbopelvic static, Posturography","RECRUITING","2026-01-01",{"date":69,"type":40},"2026-01-13",{"date":71,"type":40},"2025-11-20",{"date":73,"type":21},"2026-03",{"name":46,"class":47},""]